For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Maxim Pharmaceuticals, Inc.

USPTO Granted Patents = 27

% Expired Patents = 18.5

Trademarks = 1

Forward Citations = 169

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Svante Hermod Hermodsson (20 out of 20 patents)

Kristoffer Hellstrand (16 out of 16 patents)

Kurt R Gehlsen (14 out of 14 patents)

4. Casimir Antczak (3 out of 3 patents)

5. Wen-Lung Yeh (3 out of 3 patents)

6. Jeffry David McGolrick (3 out of 3 patents)

7. Michael Joseph Roth (3 out of 3 patents)

8. Mark Wrona (3 out of 3 patents)

9. Jan Urban Kristoffer Hellstrand (2 out of 2 patents)

10. Jan Urban Hellstrand (2 out of 2 patents)

11. Bo Svennerholm (1 out of 7 patents)

12. Lars Rymo (1 out of 8 patents)

13. Stig Jeansson (1 out of 8 patents)

14. Peter Horal (1 out of 8 patents)

15. Anders Vahlne (1 out of 8 patents)

Core Competencies:

Monocyte Maturation

Histamine Compositions

Reactive Oxygen Metabolites

Natural Killer Cells

Cancer Treatment

Topical Tissue Repair

Histamine Dihydrochloride

Synergistic Tumorcidal Response

Therapeutic Administration

Cellular Damage Prevention

Infectious Disease

Peptide Detection

27 patents: Sort by Forward Citations

1. 6893633 - Methods and compositions for promoting the maturation of monocytes (2005-05-17),

2. 6821510 - Methods and compositions for promoting the maturation of monocytes (2004-11-23),

3. 6790440 - Methods and compositions for promoting the maturation of monocytes (2004-09-14),

4. 6730692 - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage (2004-05-04),

5. 6620942 - Synthesis of histamine dihydrochloride (2003-09-16),

6. 6613788 - Elevation of circulating blood histamine levels (2003-09-02),

7. 6531120 - Ophthalmic histamine compositions and uses thereof (2003-03-11),

8. 6528654 - Synthesis of histamine dihydrochloride (2003-03-04),

9. 6498181 - Synergistic tumorcidal response induced by histamine (2002-12-24),

10. 6462067 - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage (2002-10-08),

11. 6407133 - Treatment and prevention of reactive oxygen metabolite-mediated cellular damage (2002-06-18),

12. 6403806 - Synthesis of histamine dihydrochloride (2002-06-11),

13. 6375946 - Enhanced activation of natural killer cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor (2002-04-23),

14. 6350785 - Methods and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors (2002-02-26),

15. 6305380 - Method for treatment of cancer and infectious disease (2001-10-23),

Maxim Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for serious medical conditions. The company specializes in the research and development of novel treatments, particularly in the fields of oncology and immunology. With a commitment to advancing healthcare solutions, Maxim leverages cutting-edge technology and scientific expertise to address unmet medical needs and improve patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Maxim Pharmaceuticals, Inc.

27 Patents

#221 in San Diego, CA

#2,931 in California

#12,405 in US

#23,968 in the World

San Diego, CA, United States of America

Maxim Pharmaceuticals, Inc.

Forward Citations = 169

15 inventors:

Svante Hermod Hermodsson (20 out of 20 patents)

Kristoffer Hellstrand (16 out of 16 patents)

Kurt R Gehlsen (14 out of 14 patents)

4. Casimir Antczak (3 out of 3 patents)

5. Wen-Lung Yeh (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…